F
Fabio A.B. Schutz
Researcher at Harvard University
Publications - 86
Citations - 9410
Fabio A.B. Schutz is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 29, co-authored 81 publications receiving 7604 citations. Previous affiliations of Fabio A.B. Schutz include Niigata University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery:
Stênio de Cássio Zequi,Walter Henriques da Costa,Fernando Korkes,Rodolfo Borges dos Reis,Wilson Francisco Schreiner Busato,Wagner Eduardo Matheus,Deusdedit Cortez Vieira da Silva Neto,Felipe de Almeida e Paula,Gustavo F. Carvalhal,Lucas Nogueira,Roni de Carvalho Fernandes,Adriano Gonçalves E Silva,Andre Deeke Sasse,Andre P. Fay,Denis Leonardo Jardim,Diogo Assed Bastos,Diogo Augusto Rodrigues da Rosa,Evanius Wierman,Fábio Roberto Kater,Fabio A.B. Schutz,Fernando C. Maluf,Fernando Nunes Galvão de Oliveira,Igor Alexandre Protzner Morbeck,José Augusto Rinck,Karine Martins da Trindade,Manuel Caitano Maia,Vinicius Carrera Souza,Fernando Sabino Marques Monteiro,Andrey Soares +28 more
TL;DR: This review suggests recommendations for the surgical treatment of RCC according to the LACOG-GU/LARCG experts.
Journal ArticleDOI
Hematologic toxicities in renal cell carcinoma and other malignancies treated with bevacizumab: A meta-analysis of clinical trials.
TL;DR: Conurrent use of bevacizumab with chemotherapy or immunotherapy is associated with a lower risk of high-grade anemia and an increased risk ofhigh-grade neutropenia and febrile neutropania.
Journal ArticleDOI
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
Fernando C. Maluf,Oren Smaletz,Fabio A.B. Schutz,Vinicius Carrera Souza,Andre P. Fay,Daniel Herchenhorn,Gustavo Werutsky,Telma Murias Santos +7 more
TL;DR: This study aims to evaluate the efficacy of apalutamide, a second-generation AR inhibitor, monotherapy or in combination with AA in advanced/metastatic HSPC in patients with advanced or metastatic PC with non-castrate testosterone levels.
Journal ArticleDOI
Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials.
TL;DR: Pre-clinical evidence suggests that VEGF plays a role in the homeostasis of endothelial cells, and targeted therapies have shown to be active in several malignancies.
Journal ArticleDOI
Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.
Toni K. Choueiri,Youjin Je,Guru Sonpavde,Matthew D. Galsky,Marina D. Kaymakcalan,Paul L. Nguyen,Fabio A.B. Schutz,Daniel Y.C. Heng,Christopher J. Richards +8 more
TL;DR: The use of mTOR inhibitors is associated with an increased risk of FAEs in RCC and non-RCC patients, compared with control patients, and there is no evidence of publication bias.